Resources
Share recent publications on regulatory trends, FDA programs, and oncology clinical trial
strategies, such as articles by MediRama's team on oncology drug development.
Total 116
.jpg)
View More
An Analysis of the Companion Diagnostic Approval Case That Helped Make Keytruda a Blockbuster
- 2026.02.27
- Souce: HITNEWS
.jpg)
View More
[EDGE Column] FDA Clinical Pharmacology Review Trends and Regulatory Implications for ADC Development
- 2026.02.10
- Souce: THE BIO
View More
MediRama’s Analysis of the Characteristics of 13 ADCs Approved by the U.S. FDA Published in an International Academic Journal
- 2026.01.26
- Souce: Hankyung Bio Insight
View More
MediRama published a paper in TCP Analyzing FDA Review Documents for Approved ADCs
- 2026.01.15
- Souce: THE BIO
.jpg)
View More
MediRama and the Korea Drug Research Association Successfully Conclude ‘Oncology Drug Development Strategy Training’
- 2025.10.22
- Souce: THE BIO
View More
BIX 2025: What ‘radical’ changes in US, China mean for bio sector
- 2025.10.22
- Souce: BioWorld
.jpg)
View More
[GCCL Special Contribution ②] The Significance of the FDA’s Oncology Expedited Review System and Its Strategic Utilization
- 2025.09.23
- Souce: THE BIO
.jpg)
View More
[GCCL Special Contribution ①] The Significance of the FDA’s Oncology Expedited Programs and Their Strategic Utilization
- 2025.09.19
- Souce: THE BIO
.jpg)
